Pharmaceutical intelligence for Mediar Therapeutics with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Assets: 1

Recent signals(1)

ClinicalJune 30, 2026

Phase 1 Study of MTX-439 in Diabetic Kidney Disease Patients Initiated by Mediar Therapeutics

Mediar Therapeutics has initiated Phase 1 trial to evaluate the safety and pharmacokinetics of MTX-439 in healthy adults and those with diabetic kidney disease.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJune 30, 2026

Phase 1 Study of MTX-439 in Diabetic Kidney Disease Patients Initiated by Mediar Therapeutics

Mediar Therapeutics has initiated Phase 1 trial to evaluate the safety and pharmacokinetics of MTX-439 in healthy adults and those with diabetic kidney disease.

Competitive activity

No signals indexed for this entity yet.

Assets

MTX-439 →

Therapeutic areas

Diabetic Kidney Disease →

Nephrology →

Nephrology · Diabetic Kidney Disease →

Indications

Diabetic Kidney Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.